Clinical Efficacy of Nafamostat Mesylate-assisted CRRT Therapy in SA-AKI Patients

magonlinelibrary.com March 5, 2025

Nafamostat Mesylate (NM)-assisted continuous renal replacement therapy (CRRT) therapy significantly improves the therapeutic efficacy of patients with sepsis-associated acute kidney injury (SA-AKI).

This combined approach improves immune and renal functions, reduces oxidative stress, and demonstrates a favorable safety profile, making it a viable option for clinical application.

A total of 98 patients diagnosed with SA-AKI and treated at The People’s Hospital of Pingyang between January 2022 and January 2024 were included.

The total effective rate in the NM+CRRT group was significantly higher than in the CRRT group (p < 0.05). Patients in the NM+CRRT group had significantly shorter ICU stays and lower APACHE II scores compared to those in the CRRT group (p < 0.05).